Breast carcinoma with brain metastases: Clinical analysis and immunoprofile on tissue microarrays Journal Article


Authors: Brogi, E.; Murphy, C. G.; Johnson, M. L.; Conlin, A. K.; Hsu, M.; Patil, S.; Akram, M.; Nehhozina, T.; Jhaveri, K. L.; Hudis, C. A.; Seidman, A. D.
Article Title: Breast carcinoma with brain metastases: Clinical analysis and immunoprofile on tissue microarrays
Abstract: Background: Development of brain metastasis in patients with breast carcinoma correlates with poor outcome. Identification of tumor characteristics associated with breast cancer brain metastases (BCBM) could help identify patients at risk. Patients and methods: We studied 209 patients with BCBM. We evaluated a panel of proteins relevant to the biology of breast carcinoma on tissue microarrays of 133 primary tumors and 56 BCBM, including paired samples from 43 patients, and correlated the findings with the clinical outcome. Results: The median survival after BCBM diagnosis was 19 months (95% confidence interval, 13-23 months). Patients presenting with solitary metastasis had a significantly longer median survival than those with multiple lesions (25 versus 11 months, P ≤ 0.0001). We found no significant discordance in the expression of tested markers, but identified a possible association between the expression of basal cytokeratin CK5/6 in the primary carcinoma and the development of multiple rather than solitary brain metastases. Conclusions: Expression of antigens commonly associated with breast carcinoma does not differ significantly between the primary tumor and the corresponding brain metastases. Although no specific immunoprofile identifies breast carcinomas that develop brain metastases, we observed a possible association between CK5/6 expression in the primary tumor and multiple versus solitary BCBM. © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.
Keywords: adult; cancer survival; human tissue; protein expression; aged; aged, 80 and over; disease-free survival; middle aged; primary tumor; survival rate; major clinical study; clinical feature; cancer localization; outcome assessment; brain neoplasms; cancer diagnosis; protein localization; antigen expression; protein analysis; disease association; clinical assessment; tumor markers, biological; breast neoplasms; retrospective study; tumor marker; carcinogenesis; breast carcinoma; carcinoma; brain metastasis; tissue array analysis; immunoassay; tissue microarray; egfr; cytokeratin 5; cytokeratin 6; estrogen receptor; triple negative; her2; kaplan-meier estimate; cytokeratin 5/6; basal breast carcinoma; keratin-5; keratin-6
Journal Title: Annals of Oncology
Volume: 22
Issue: 12
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2011-12-01
Start Page: 2597
End Page: 2603
Language: English
DOI: 10.1093/annonc/mdr022
PROVIDER: scopus
PUBMED: 21427063
DOI/URL:
Notes: --- - "Export Date: 3 January 2012" - "Art. No.: mdr022" - "CODEN: ANONE" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Sujata Patil
    511 Patil
  2. Meier Hsu
    169 Hsu
  3. Andrew D Seidman
    319 Seidman
  4. Clifford Hudis
    905 Hudis
  5. Alison Katherine Conlin
    18 Conlin
  6. Melissa Lynne Johnson
    19 Johnson
  7. Conleth Gerrard Murphy
    18 Murphy
  8. Komal Lachhman Jhaveri
    220 Jhaveri
  9. Edi Brogi
    522 Brogi
  10. Muzaffar M Akram
    92 Akram